SIXTH FRAMEWORK PROGRAMME PRIORITY 1
Life Sciences, Genomics and Biotechnilogy for Health
SPECIFIC TARGETED RESEARCH OR INNOVATION PROJECT
Immune response to viral respiratory infections and vaccination in the elderly
Project acronym: RespViruses
Viruses: HCoV-NL63 / HMPV / RSV / EBV / H5N1
Multidisciplinary scientific network:
University Hospital Bonn, University of Siena, Academic Medical Center Amsterdam, University Hospital Dijon, Hamann Softwaredevelopement, RNA-Tec, INGENASA, University Hospital Aachen
Countries: Germany, Italy, Netherlands, France, Belgium, Spain
During the last years some new respiratory viruses (HMPV/hCoV-NL63/SARS/Bocavirus/flu H5N1) have emerged. In addition to other viruses, such as RSV, EBV, and Paramyxoviruses, they are able to induce severe respiratory diseases in high risk patients, in particular in the elderly.
- new antibody based assays will be developed within the project
- genomics and proteomics methodologies would be performed to develop new assays for diagnostic purposes of new emerging respiratory viruses
- new strategies to compensate immuno-senescence will be investigated to stimulate and assist the immune system in defending the disease
- novel software will be developed, for better and standardized definition of parameters that can characterize a specific virus infection
The project will significantly contribute to the generation of new knowledge concerning the understanding
of the elderly immune response to the viruses investigated. Moreover, it will provide important insights
in the native and acquired sero-prevalence to those pathogens. Due to its epidemiological aspects, the
project will be of significant importance to the European community.
The project will provide new strategies for the prevention and treatment of viral respiratory infections in the elderly. What is more, it will eventually contribute to the development of new drugs, vaccines, or immuno-adjuvants, as well as the implementation of new diagnostic assays.
We expect to gain detailed knowledge on the innate and acquired immune response to emerging respiratory viruses in the elderly.
A thorough basic investigation of emerging respiratory viruses will provide further handles to develop antiviral strategies, and (known) antivirals will be evaluated with the final goal to support the elderly's immune response whilst reducing mortality caused by respiratory infections in the elderly.